AI Article Synopsis
- MOGAD is a specific type of central nervous system demyelinating disease treated with immunoglobulin (Ig) to help prevent relapses, but its effect on serum MOG-IgG levels is not well understood.
- A study involving 10 patients with MOGAD showed that most maintained MOG-IgG positivity and exhibited reduced or stable titers while receiving Ig treatment, even without disease activity.
- The findings indicate that Ig therapy's effectiveness in MOGAD may not solely rely on lowering MOG-IgG levels.
Article Abstract
Background: Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a distinct demyelinating disease of the central nervous system. Immunoglobulin (Ig) has been used as a maintenance therapy to prevent relapses in MOGAD, but the impact of Ig on serum MOG-IgG titers is unclear.
Objective: To characterize the variation in serum MOG-IgG titers after initiation of Ig treatment in people with MOGAD.
Methods: We conducted a retrospective study of 10 patients with a diagnosis of MOGAD and available serum MOG-IgG titers before and after initiation of maintenance Ig treatment.
Results: We found that most of the patients remained MOG-IgG seropositive while on Ig treatment with a reduced or unchanged titer, despite a lack of disease activity.
Conclusions: This case series suggests that the mechanism of action of Ig therapy in MOGAD is not exclusively dependent on MOG-IgG titer reduction.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/13524585231211119 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!